1. Home
  2. TONX vs CHRS Comparison

TONX vs CHRS Comparison

Compare TONX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TON Strategy Company

TONX

TON Strategy Company

HOLD

Current Price

$2.98

Market Cap

147.6M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.02

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TONX
CHRS
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.6M
159.1M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
TONX
CHRS
Price
$2.98
$1.02
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
182.4K
★ 1.3M
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
69.21
★ 472.00
EPS
★ N/A
N/A
Revenue
★ $32,000.00
N/A
Revenue This Year
N/A
$44.19
Revenue Next Year
N/A
$65.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 433.33
N/A
52 Week Low
$1.75
$0.94
52 Week High
$4.44
$2.62

Technical Indicators

Market Signals
Indicator
TONX
CHRS
Relative Strength Index (RSI) 44.30 40.32
Support Level $2.85 $0.97
Resistance Level $3.58 $1.53
Average True Range (ATR) 0.17 0.07
MACD -0.03 0.00
Stochastic Oscillator 39.07 36.84

Price Performance

Historical Comparison
TONX
CHRS

About TONX TON Strategy Company

TON Strategy Co is a digital asset treasury and Web3 ecosystem company focused on supporting The Open Network, a public blockchain integrated with Telegram and designed for fast, scalable transactions and decentralized applications. Its core business is managing its holdings of Toncoin (TON), including staking tokens to support network validation and earn rewards, while adhering to regulatory, accounting, and risk management standards. The company also pursues Web3 initiatives to support the ecosystem's growth and adoption. It operates through MARKET. live, Go Fund Yourself, and TON segments, with MARKET.live generating maximum revenue as a multi-vendor livestream shopping platform that combines e-commerce and entertainment across social and video channels.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: